Thermo Fisher Scientific's Urmi Prasad Richardson explores what still needs to be done to deliver on the promise of gender inclusion and elevate female leadership in business
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh